BioSpace News Archive

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with ENHANZE® for subcutaneous (SC) use for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide), for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Marius Pharmaceuticals announced today its sponsorship of the AXYS 2023 Virtual Family Conference.

Pearl Bio , a synthetic biology company backed by Khosla Ventures, is recoding life to create a new era of biologics and biomaterials.

PaxMedica, Inc. announced that its CEO, Howard Weisman, participated in a webcast on Saturday, June 17th, hosted by The BRAIN Foundation.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR) today announced results from the Company’s Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoid symptoms.

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced upcoming presentations by the Company and collaborators at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 24 – 27, 2023, in Chicago, Ill.

RenovoRx, Inc today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB).

Blue Earth Therapeutics today announced upcoming presentations by the Company and a collaborator at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 24 – 27, 2023 in Chicago, Ill.

Galecto, Inc. announced that it is set to join the Russell Microcap Index at the conclusion of the 2023 Russell index annual reconstitution, effective after the U.S. market opens on Monday, June 26, 2023, according to the preliminary list of Russell Microcap additions posted on June 16, 2023.